[1] d'Arcangues C. Worldwide use of intrauterine devices for contraception. Contraception 2007;75:S2-7.
[2] Daniels K,Abma J. Current contraceptive status among women aged 15–49: United States, 2015–2017, in NCHS Data Brief 2018, National Center for Health Statistics: Hyattsville, MD.
[3] Long-term reversible contraception. Twelve years of experience with the TCu380A and TCu220C. Contraception 1997;56:341-52.
[4] Garbers S, Haines-Stephan J, Lipton Y, Meserve A, Spieler L,Chiasson MA. Continuation of copper-containing intrauterine devices at 6 months. Contraception 2013;87:101-6.
[5] Grunloh DS, Casner T, Secura GM, Peipert JF,Madden T. Characteristics associated with discontinuation of long-acting reversible contraception within the first 6 months of use. Obstet Gynecol 2013;122:1214-21.
[6] Rowe P, Farley T, Peregoudov A, Piaggio G, Boccard S, Landoulsi S, et al. Safety and efficacy in parous women of a 52-mg levonorgestrel-medicated intrauterine device: a 7-year randomized comparative study with the TCu380A. Contraception 2016;93:498-506.
[7] Godfrey EM, Folger SG, Jeng G, Jamieson DJ,Curtis KM. Treatment of bleeding irregularities in women with copper-containing IUDs: a systematic review. Contraception 2013;87:549-66.
[8] Moher D, Jones A, Lepage L,Group C. Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. Jama 2001;285:1992-5.
[9] Vitonis AF, Vincent K, Rahmioglu N, Fassbender A, Buck Louis GM, Hummelshoj L, et al. World Endometriosis Research Foundation Endometriosis Phenome and biobanking harmonization project: II. Clinical and covariate phenotype data collection in endometriosis research. Fertil Steril 2014;102:1223-32.
[10] Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N,Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377-81. doi: 10.1016/j.jbi.2008.08.010. Epub Sep 30.
[11] Mishell DR, Jr., Guillebaud J, Westhoff C, Nelson AL, Kaunitz AM, Trussell J, et al. Recommendations for standardization of data collection and analysis of bleeding in combined hormone contraceptive trials.[see comment]. Contraception 2007;75:11-5.
[12] Curtis KM, Jatlaoui TC, Tepper NK, Zapata LB, Horton LG, Jamieson DJ, et al. U.S. selected practice recommendations for contraceptive use, 2016. MMWR Recomm Rep 2016;65:1-66.
[13] Clue, URL|; Year Last Update Date| [cited Access Year Access Date]|.
[14] McNicholas C, Madden T, Secura G,Peipert JF. The contraceptive CHOICE project round up: what we did and what we learned. Clin Obstet Gynecol 2014;57:635-43.
[15] US Food and Drug Administration. NDAC Briefing Document: Review of Safety and Efficacy of OTC Naproxen Sodium. Non-prescription drug advisory committee.
[16] DeArmond B, Francisco CA, Lin JS, Huang FY, Halladay S, Bartziek RD, et al. Safety profile of over-the-counter naproxen sodium. Clin Ther 1995;17:587-601; discussion 586.
[17] Cohen MA, Simmons KB, Edelman AB,Jensen JT. Tamoxifen for the prevention of unscheduled bleeding in new users of the levonorgestrel 52-mg intrauterine system: a randomized controlled trial. Contraception 2019;100:391-6.
[18] Kaneshiro B, Edelman A, Carlson NE, Nichols M, Forbes MM,Jensen J. A randomized controlled trial of subantimicrobial-dose doxycycline to prevent unscheduled bleeding with continuous oral contraceptive pill use. Contraception 2012;85:351-8.
[19] Zigler RE, Madden T, Ashby C, Wan L,McNicholas C. Ulipristal Acetate for Unscheduled Bleeding in Etonogestrel Implant Users: A Randomized Controlled Trial. Obstet Gynecol 2018;132:888-94.
[20] Diedrich JT, Desai S, Zhao Q, Secura G, Madden T,Peipert JF. Association of short-term bleeding and cramping patterns with long-acting reversible contraceptive method satisfaction. Am J Obstet Gynecol 2014;18:025.
[21] Grimes DA, Hubacher D, Lopez LM,Schulz KF. Non-steroidal anti-inflammatory drugs for heavy bleeding or pain associated with intrauterine-device use. Cochrane Database Syst Rev 2006:CD006034.
[22] Di Lieto A, Catalano D, Miranda L,Paladini A. Action of a prostaglandin synthetase inhibitor on IUD associated uterine bleeding. Clin Exp Obstet Gynecol 1987;14:41-4.
[23] Pedron N, Lozano M,Aznar R. Treatment of hypermenorrhea with mefenamic acid in women using IUDs. Contracept Deliv Syst 1982;3:135-9.
[24] Toppozada M, Anwar M, Abdel Rahman H,Gaweesh S. Control of IUD-induced bleeding by three non-steroidal anti-inflammatory drugs. Contracept Deliv Syst 1982;3:117-25.
[25] Ylikorkala O,Viinikka L. Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices. Br J Obstet Gynaecol 1983;90:78-83.
[26] Davies AJ, Anderson AB,Turnbull AC. Reduction by naproxen of excessive menstrual bleeding in women using intrauterine devices. Obstet Gynecol 1981;57:74-8.
[27] Lalos O,Nilsson B. Dysmenorrhea in women with intrauterine contraceptive device. Treatment with a prostaglandin synthetase inhibitor, naproxen. Int J Gynaecol Obstet 1983;21:33-7.
[28] Magnay JL, O'Brien S, Gerlinger C,Seitz C. A systematic review of methods to measure menstrual blood loss. BMC Womens Health. 2018;18:142. doi: 10.1186/s12905-018-0627-8.
[29] Hobby JH, Zhao Q,Peipert JF. Effect of baseline menstrual bleeding pattern on copper intrauterine device continuation. Am J Obstet Gynecol 2018;219:465.e1-.e5.
[30] Sanders JN, Turok DK, Gawron LM, Law A, Wen L,Lynen R. Two-year continuation of intrauterine devices and contraceptive implants in a mixed-payer setting: a retrospective review. Am J Obstet Gynecol 2017;216:590.e1-.e8.
[31] Bryant-Smith AC, Lethaby A, Farquhar C,Hickey M. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev. 2018;4:CD000249.:10.1002/14651858.CD000249.pub2.